Surgical Treatment of Craniofacial Fibrous Dysplasia With TP53 Gene Mutation.

Autor:	Chen L; Department of Neurosurgery, Yangtze River Shipping General Hospital, Wuhan Brain Hospital, Wuhan City, Hubei Province., Chen Y; The Eighth Clinical Medical School of Guangzhou University of Chinese Medicine, Foshan, Guangdong Province, China., Xiao K; Department of Neurosurgery, Yangtze River Shipping General Hospital, Wuhan Brain Hospital, Wuhan City, Hubei Province., Hu F; Department of Neurosurgery, Yangtze River Shipping General Hospital, Wuhan Brain Hospital, Wuhan City, Hubei Province., Wang H; Department of Neurosurgery, Yangtze River Shipping General Hospital, Wuhan Brain Hospital, Wuhan City, Hubei Province., Shao Q; Department of Neurosurgery, Yangtze River Shipping General Hospital, Wuhan Brain Hospital, Wuhan City, Hubei Province.
Jazyk:	angličtina
Zdroj:	The Journal of craniofacial surgery [J Craniofac Surg] 2024 Mar-Apr 01; Vol. 35 (2), pp. 608-610. Date of Electronic Publication: 2023 Nov 20.
DOI:	10.1097/SCS.0000000000009900
Abstrakt:	Background: To report the surgical treatment of craniofacial fibrous dysplasia (CFD) with TP53 gene mutation. Methods: The patient was diagnosed with CFD by surgery at the age of 14 years. At the age of 35 years, the tumor recurred, and the patient took active treatment. The tumor was resected 4 times by neuroendoscopy due to recurrence in a short period. Meanwhile, genetic tests were performed on the patient. The patient's postoperative pathology indicated leiomyosarcoma and genetic testing indicated TP53 gene mutation. Results: Despite the active surgical treatment, the patient finally died of a malignant tumor. The prognosis of patients with CFD malignancy accompanied by TP53 gene mutation is poor, and its treatment is difficult. Conclusions: The prognostic benefit of surgical treatment for patients with CFD malignancy is limited. It is hoped that more genetic mutations will be identified and reported in patients with CFD malignancy, and long-term follow-up is necessary for patients with current fibrous dysplasia or CFD. Competing Interests: The authors report no conflicts of interest. (Copyright © 2023 by Mutaz B. Habal, MD.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu